bmimd semaglutide cuts BMI by 19% in treatment-resistant young adults with severe obesity, finds trial Who Qualifies for Semaglutide GLP-1

Semaglutide, a glucagon-like peptide receptor agonist (GLP- 1 RA), was shown in STEP 1 to produce mean weight reduction from baseline to week 68 of 14.9% for semaglutide versus 2.4% for placebo, by treatment-policy or treatment-regimen estimand which is reported throughout this manuscript, except where noted [1]

Consult your mental health provider before starting any GLP-1 medication

V.et al (2017)

Explore the PlexusDx approach: the Weight Management Protocols, or start with the Precision Peptide Genetic Test to map your GLP-1 pathway first

These documents outline the rights and responsibilities of both patients and suppliers, helping to prevent misunderstandings and legal issues

This helps prevent your blood sugar from getting too high